Division of Cardiothoracic Surgery, Department of Surgery, Medical University of South Carolina, Charleston, South Carolina 29424, USA.
Ann Thorac Surg. 2010 Nov;90(5):1411-7. doi: 10.1016/j.athoracsur.2010.05.036.
Need for pacemaker or internal cardioverter defibrillator lead removal is increasing. Removal can be dangerous, difficult, or unsuccessful.
We retrospectively reviewed our results and the techniques we used in 365 patients from 1992 through 2009 for successful complete removal of leads and complications. Various techniques of extraction were analyzed for effectiveness and complications. The eras before (1992 to 1999) and after the availability of laser sheath extraction (2000 to 2009) are compared.
Of 365 patients who underwent transvenous lead extraction, of which 235 were infected, and 130 had lead removal for noninfectious indication. Staphylococcus aureus was the infecting organism in 40%, and coagulase-negative Staphylococcus occurred in 33%. One-half of the organisms were methicillin resistant. Preimplant risk factors for infection included more than one device implant procedure in 105 (47%), preimplant Coumadin therapy (Bristol-Myers Squibb, Princeton, NJ) in 74 (31%), and hemodialysis in 9 (4%). Laser extraction became available in 2000. The era with the availability of laser extraction was associated with a better complete extraction rate (93% vs 89.55%) a lower bleeding rate (1.9% vs 3.1%), and complete extraction without the additional use of femoral workstation extraction tools. Mortality was 1.1%. No death was due to device removal. All deaths were the result of severe preoperative and continuing postextraction sepsis.
A lead extraction protocol that included procedures done in an operating room environment allowing rapid, open intervention for bleeding, a varied choice of extraction tools, arterial line monitoring, transesophageal echocardiography, general anesthesia, and an experienced team yielded complete extraction in more than 90% of patients, with a low complication rate and no procedurally related deaths.
需要移除起搏器或内置心脏除颤器的导线的情况越来越多。移除导线可能会很危险、困难或不成功。
我们回顾了从 1992 年到 2009 年期间 365 名患者的结果和使用的技术,这些患者成功地完全移除了导线并处理了并发症。分析了各种提取技术的有效性和并发症。比较了在激光鞘提取可用之前(1992 年至 1999 年)和之后(2000 年至 2009 年)的时期。
在 365 名接受经静脉导线拔除术的患者中,235 名患有感染,130 名因非感染性原因而需要拔除导线。感染的病原体 40%为金黄色葡萄球菌,33%为凝固酶阴性葡萄球菌。一半的病原体对甲氧西林耐药。感染的植入前危险因素包括 105 例(47%)超过一次装置植入程序、74 例(31%)植入前华法令治疗(Bristol-Myers Squibb,新泽西州普林斯顿)和 9 例(4%)血液透析。激光提取于 2000 年开始使用。在激光提取可用的时代,完全提取率更高(93%比 89.55%),出血率更低(1.9%比 3.1%),无需额外使用股动脉工作站提取工具即可完全提取。死亡率为 1.1%。没有死亡是由于设备移除。所有死亡都是严重的术前和持续的术后败血症的结果。
包括在手术室环境中进行的程序,允许快速、开放干预出血,多种提取工具的选择,动脉线监测,经食管超声心动图,全身麻醉和有经验的团队,为超过 90%的患者提供了超过 90%的完全提取,并发症发生率低,没有与程序相关的死亡。